Aurigene Pharmaceutical Services provides a flexible and wide range of services and capabilities at each phase of drug lifecycle.
- End-to-end services across the drug lifecycle.
- Integrated services and resources enabling seamless and accelerated development from discovery to commercialization.
- Capabilities to supply from gram scale to multi-ton scale of active ingredients and complex intermediates.
- Core areas of competence in specialized chemistry (peptides, carbohydrates, steroids, mPEGs).
- Standalone and integrated discovery services.
- World-class infrastructure: State-of-the-art R and D and manufacturing facilities audited by major international regulatory agencies.
- Biotherapeutic modalities including proteins, antibodies, ADCs, CAR Ts, mRNAs.
- Drug product capabilities from formulation development to commercial production in GMP facilities.
Hit Generation
Lead
IdentificationLead
Optimization
- Early stage drug discovery accelerating innovations for small and large molecules.
- FTE/FFS services in medicinal chemistry, computational chemistry, discovery biology. and large molecule modalities.
Development
Phase 1Development:
Phase 2Development:
Phase 3
- Helping our partners to bring their innovations to the market faster through phase appropriate development services.
- Process development and non-GMP supplies and technology transfer.
- GMP clinical supplies for API and drug product.
Commercial
Manufacturing
- Ensuring a sustainable supply of APIs and finished formulations.
- Continuous improvement and reliable commercial supplies from 8 US FDA inspected facilities.
Range of our services
Aurigene Pharmaceutical Services offers end-to-end capabilities across drug discovery, development and manufacturing of APIs and formulations. We have discovery, development and manufacturing operations in multiple technology platforms including carbohydrates, steroids, PEG derivatives, oligonucleotides, steroids, high-potent APIs and peptides. In addition, we run discovery scale and CDMO scale operations in biotherapeutics services such as ADCs, mAbs, mRNAs and CAR Ts.
Aurigene Pharmaceutical Services CRO/CDMO
Small
Molecules
Large Molecules
Biotherapeutics
Formulation
Services
Formulation Services
Early phase formulation development, Preformulation, Drug product characterization studies and testing, Pharmaceutical stability studies
Why Aurigene Pharmaceutical Services?
Our focus on scientific expertise and integrated services along with our strong fundamentals on quality infrastructure, sustainability operations, and information security makes us a preferred partner.
Truly integrated services
We offer one-stop solutions for
- Integrated Discovery chemistry and Biology services
- Small molecule and Large molecule services
- Services from early discovery to commercialization
- Global regulatory and quality expertise
- Pre-formulation and formulation service
- Analytical and purification expertise
Quality
- Our R and D site is US FDA inspected cGMP sites have multiple accreditations across globe, All our labs are GLP approved, animal facilities are AAALAC accredited
Science
- Strong technology platforms Niche/Sensitive/Complex chemistry expertise
Infrastructure
- 2 R and D centers, 8 US FDA inspected cGMP sites, AAALAC accredited vivarium
Information Security
- 360-degree information security coverage with adequate back-up plan, business continuity plan and information security interventions
Business Continuity
- Structured assurance and governance measures
People
- We strive to hire the best talent and train them,
700+ scientists, >95% of scientists are post-graduates or above
ESG
- Commitment to highest standards of Environment, Social and Governance; Dow Jones, CDP, PSCI, approved
Resources
SEPTEMBER 04, 2023
Why meet us at CPHI Barcelona?
Discover the Opportunities: Visit Aurigene Pharmaceutical Services at CPHI BarcelonaThe Contract Research, Development and Manufacturing Organization (CRDMO) industry is a dynamic and rapidly evolving sector emerging as it plays a vital role in providing a wide range of services enabling drug companies to bring their products to market efficiently and effectively...
Read More
Immuno Oncology - Therapies and Challenges
With more than 200 distinct cancer types recognized and steady increase in cancer incidence rates, the fight with cancer takes a new shape with each emerging decade. First was surgery, followed by radiotherapy and chemotherapy. The fourth one was targeted cancer therapeutics, also known as precision therapies. Precision therapies were established with the discove...
Read More
Anti-Infective Drug Discovery
Objective & Challenges: Objective was to identify an optimized anti-bacterial lead molecule with in vivo efficacy in relevant infection models an acceptable safety profile, and a patentable series. Challenge was to develop a more efficacious compound than the reference standard.Study design: Compounds were designed and synth...
Read More
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2005
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.